I studie WV16241 var primære endepunkter for effekt normalisering af ALAT og HBV - DNA under 2 x 104 kopier/ ml.
In study WV16241, the primary efficacy endpoints were ALT normalisation and HBV-DNA below 2 x 104 copies/ ml.